Publication

Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs

Related publications (35)

About
Privacy
Disclaimer

Graph Chatbot

Chat with Graph Search

Ask any question about EPFL courses, lectures, exercises, research, news, etc. or try the example questions below.

DISCLAIMER: The Graph Chatbot is not programmed to provide explicit or categorical answers to your questions. Rather, it transforms your questions into API requests that are distributed across the various IT services officially administered by EPFL. Its purpose is solely to collect and recommend relevant references to content that you can explore to help you answer your questions.

Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs

Graph Chatbot

Chat with Graph Search

Reaction Mechanism and Catalytic Fingerprint of Allantoin Racemase

[Fe]-hydrogenase and Models Containing An Iron-Acyl Ligation

On the active site of mononuclear B1 metallo beta-lactamases: a computational study

Fragmentation methods on the balance: unambiguous top–down mass spectrometric characterization of oxaliplatin–ubiquitin binding sites

Thioredoxin reductase, an emerging target for anticancer metallodrugs

Studies of Glutathione Transferase P1-1 Bound to a Platinum(IV)-Based Anticancer Compound Reveal the Molecular Basis of Its Activation

Deamidation and Transamidation of Substance P by Tissue Transglutaminase Revealed by Electron-Capture Dissociation Fourier Transform Mass Spectrometry (Chem. Eur. J. 2/2011)

Method and compositions for inhibition of macrophage migration inhibitory factor (mif)

Structure of Zirconocene Complexes Relevant for Olefin Catalysis: Infrared Fingerprint of the Zr(C5H5)(2)(OH)(CH3CN)(+) Cation in the Gas Phase

Development of Bimetallic Titanocene-Ruthenium-Arene Complexes As Anticancer Agents: Relationships between Structural and Biological Properties